Phase I trial to investigate ascending multiple doses of FV 100 in volunteers.
Latest Information Update: 14 Aug 2009
Price :
$35 *
At a glance
- Drugs Valnivudine (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Pharmacokinetics
- 10 Feb 2009 Results reported by Inhibitex. Results will be presented at a scientific conference later in 2009.
- 10 Feb 2009 Status changed from recruiting to completed as reported by Inhibitex.
- 29 Apr 2008 The Investigational New Drug application for FV 100 has been accepted by the FDA, reported Inhibitex.